Japanese Patient Payments "Must Rise"

30 June 1996

In Japan, a government advisory panel has recommended that patients be made to pay up to 40% of their medicine charges, and that the elderly be billed higher rates for medical treatment.

The proposals are contained in an interim report by the Medical Insurance System Council, an advisory body to Health and Welfare Minister Naoto Kan. In November, the panel is to issue its final report on reform of the health insurance system, which is troubled financially by the aging society and slower economic growth. The reform is also aimed at saving insurance plans now operating in the red.

At present, insurance covers 70%-90% of the cost of medicines, but the Council recommends cutting this to 50%. Also, it suggests that patients carry a heavier burden by raising their share of treatment costs by 10%-20%. But reduction of drug costs is the main target, since they accounted for 29.5% of Japan's total medical spending of $252 billion in fiscal 1995 (to March 31, 1996). Compounding the problem is the fact that Japanese doctors overprescribe because of the reimbursement system. The Ministry of Health and Welfare has imposed some curbs on prescriptions, but they have fallen far short of solving the problem.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight